Immune modulation and adjunctive immunotherapy — compounds assessed
The 5 compounds the Institute assesses in immune modulation and adjunctive immunotherapy.
§4Compounds assessed
Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.
-
Meta-analyses of hepatitis B trials report higher sustained virological response with thymosin alpha-1 as monotherapy or adjunct; a large Chinese randomised trial in sepsis reported a mortality difference that a subsequent larger trial did not confirm — Rated…
Moderate -
Russian clinical reports describe immunological and clinical effects across a wide range of conditions — For a substance of undefined composition, the Institute cannot in principle assign a certainty rating above very low, because the intervention itself is…
Very low -
No assessable evidence identified — —
Not rated -
No assessable randomised evidence for immune outcomes — —
Not rated -
No randomised human evidence for systemic immune effects — —
Not rated
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Garaci E, Pica F, Serafino A, Balestrieri E, Matteucci C, Moroni G, Sorrentino R, Zonfrillo M, Pierimarchi P, Sinibaldi-Vallebona P. Thymosin α1 and cancer: action on immune effector and tumor target cells. Annals of the New York Academy of Sciences 2012;1269:26–33. doi:10.1111/j.1749-6632.2012.06697.x · PMID 23045967
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.